- Home
- FCT vs ATAI Comparison
FCT vs ATAI Comparison
Compare FCT & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCT
- ATAI
- Stock Information
- Founded
- FCT 2004
- ATAI 2018
- Country
- FCT United States
- ATAI Germany
- Employees
- FCT N/A
- ATAI N/A
- Industry
- FCT Finance Companies
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- FCT Finance
- ATAI Health Care
- Exchange
- FCT Nasdaq
- ATAI Nasdaq
- Market Cap
- FCT 266.8M
- ATAI 214.8M
- IPO Year
- FCT N/A
- ATAI 2021
- Fundamental
- Price
- FCT $10.28
- ATAI $1.24
- Analyst Decision
- FCT
- ATAI Strong Buy
- Analyst Count
- FCT 0
- ATAI 4
- Target Price
- FCT N/A
- ATAI $9.00
- AVG Volume (30 Days)
- FCT 106.8K
- ATAI 1.3M
- Earning Date
- FCT 01-01-0001
- ATAI 11-13-2024
- Dividend Yield
- FCT 11.29%
- ATAI N/A
- EPS Growth
- FCT N/A
- ATAI N/A
- EPS
- FCT N/A
- ATAI N/A
- Revenue
- FCT N/A
- ATAI $331,000.00
- Revenue This Year
- FCT N/A
- ATAI $93.15
- Revenue Next Year
- FCT N/A
- ATAI N/A
- P/E Ratio
- FCT N/A
- ATAI N/A
- Revenue Growth
- FCT N/A
- ATAI N/A
- 52 Week Low
- FCT $9.45
- ATAI $1.03
- 52 Week High
- FCT $10.42
- ATAI $2.85
- Technical
- Relative Strength Index (RSI)
- FCT 45.38
- ATAI 33.95
- Support Level
- FCT $10.25
- ATAI $1.15
- Resistance Level
- FCT $10.44
- ATAI $1.69
- Average True Range (ATR)
- FCT 0.09
- ATAI 0.11
- MACD
- FCT -0.01
- ATAI -0.06
- Stochastic Oscillator
- FCT 21.81
- ATAI 3.69
About FCT First Trust Senior Floating Rate Income Fund II of Beneficial Interest
First Trust Senior Floating Rate Income Fund II is the United States based diversified, closed-end management investment company. Its investment objective is to seek a high level of current income. As a secondary objective, the fund attempts to preserve capital. The fund seeks to achieve the objectives by investing in a portfolio of senior floating-rate loan interests. Its portfolio of investments consists of aerospace and defense, agricultural products, broadcasting, cable and satellite, electric utilities and other sectors.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.